RT @DrPetryna: Abst1773 #ACR21 @rheumnow guselkumab outperforms ustekinumab in both msk & skin domains in bio naive

Social Author Image
https://pbs.twimg.com/profile_images/1010360126954491904/BUlKU6N_.jpg
Tweet Author
DrPetryna
Social Author Name
Olga Petryna
Tweet Content
Abst1773 #ACR21 @rheumnow guselkumab outperforms ustekinumab in both msk & skin domains in bio naive & bio experienced alike- data from pivotal Phase III trials : at weeks 52 GUS better ACR20, PASI100 in both doses vs Stelara https://t.co/lfddaCJA5O
Show on Archive Page
On
Display in Search Results
On
PDQ
Off

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×